Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Change in cardiovascular risk profile in people with human immunodeficiency virus infection: a-12 months follow up

Jurnal Ners · Vol. 21 No. 1 (2026) · hlm. 67–75

DOI
10.20473/jn.v21i1.72933
ISSN
2502-5791, 1858-3598
Terbit
2026-02-28
Penerbit
Universitas Airlangga
Bahasa
eng
Lisensi
creativecommons.org/licenses/by/4.0

Abstrak

Introduction: This study aimed to evaluate longitudinal changes in CVD risk and identify the contributing factors among HIV-positive individuals. Methods: A 12-month prospective study was conducted at an AIDS treatment center in southern Taiwan. A total of 411 adults living with HIV, aged 18 years or older, with no history of CVD treatment, were enrolled. CVD risk was assessed at baseline and 6 and 12 months using the D:A:D risk prediction model. Mixed-effects models were used to examine associated factors. Results: participants ranged in age from 19 to 77 years, with 95.9% being male. At baseline, 47% of the patients were low-risk, 37.7% were moderate-risk, 10.9% were high-risk, and 4.4% were very high-risk. After 12 months, 19% of participants showed a reduction in CVD risk. Increased risk was significantly associated with hepatitis C co-infection, use of lopinavir- or abacavir-based ART, and a longer duration of lopinavir exposure. Conversely, reductions in CVD risk were linked to higher educational attainment, use of antihypertensive or lipid-lowering therapy, and adherence to a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-based antiretroviral therapy regimen. Conclusions: CVD risk in PLHIV is dynamic and modifiable. The use of NNRTI-based regimens and lipid-lowering therapies contributed to a significant risk reduction. Comprehensive integrated management strategies addressing both HIV infection and cardiovascular health are essential. Further research is needed on the cardiovascular effects of integrase inhibitors (INSTIs), particularly their long-term effects on lipid profiles and endothelial function.

Jaringan kolaborasi para penulis

33 penulis · 79 tautan kepenulisan bersama · 45 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Padjadjaran University
  • STIKep PPNI Jawa Barat
  • National Cheng Kung University Hospital
  • Universiti of Malaysia Sabah
  • State University of Jakarta
  • Lincoln University College
  • National Cheng Kung University
  • Organisasi lain
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Heni PurnamaSTIKep PPNI Jawa Barat3
Wen‐Chien KoNational Cheng Kung University3
Jung-Der WangNational Cheng Kung University3
Taryudi TaryudiState University of Jakarta2
Nyayu Nina Putri CalisanieSTIKep PPNI Jawa Barat2
Faridah Mohd SaidLincoln University College1
Wini HadiyaniSTIKep PPNI Jawa Barat1
Nisha NambiarLincoln University College1
Windy RakhmawatiPadjadjaran University1
Neti JuniartiPadjadjaran University1
Taryudi TaryudiState University of Jakarta1
Muhammad Rif'anAfiliasi tidak diketahui1
Nenden Nur Asriyani MaryamPadjadjaran University1
Irma DarmawatiIndonesia University of Education1
Pujowati PujowatiDr. Hasan Sadikin General Hospital1
Tuty YanuartiUniversiti of Malaysia Sabah1
Mohd Nazri Mohd DaudUniversiti of Malaysia Sabah1
Noor Hassline MohamedUniversiti of Malaysia Sabah1
Azman AtilUniversiti of Malaysia Sabah1
Aan NuraeniPadjadjaran University1
Anastasia AnnaPadjadjaran University1
Ying‐Chin LiaoDalin Tzu Chi Hospital1
Iyus YosepPadjadjaran University1
Anisa Dwi PutriAfiliasi tidak diketahui1
Astri MutiarAfiliasi tidak diketahui1
Gilang Dwi PratiwiAfiliasi tidak diketahui1
Vita LucyaAfiliasi tidak diketahui1
Santi SusantiSTIKep PPNI Jawa Barat1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://e-journal.unair.ac.id/index.php/JNERS/oai, pertama di-harvest 9 Nov 2026, terakhir terlihat 9 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Change in cardiovascular risk profile in people with human immunodeficiency virus infection:  a-12 months follow up</dc:title>
	<dc:creator>Lindayani, Linlin </dc:creator>
	<dc:creator>Lai, Yiin</dc:creator>
	<dc:creator>Ko, Wen Chien </dc:creator>
	<dc:creator>Wang, Jung-Der </dc:creator>
	<dc:creator>Ko, Nai Ying</dc:creator>
	<dc:description xml:lang="en-US">Introduction: This study aimed to evaluate longitudinal changes in CVD risk and identify the contributing factors among HIV-positive individuals.
Methods: A 12-month prospective study was conducted at an AIDS treatment center in southern Taiwan. A total of 411 adults living with HIV, aged 18 years or older, with no history of CVD treatment, were enrolled. CVD risk was assessed at baseline and 6 and 12 months using the D:A:D risk prediction model. Mixed-effects models were used to examine associated factors.
Results: participants ranged in age from 19 to 77 years, with 95.9% being male. At baseline, 47% of the patients were low-risk, 37.7% were moderate-risk, 10.9% were high-risk, and 4.4% were very high-risk. After 12 months, 19% of participants showed a reduction in CVD risk. Increased risk was significantly associated with hepatitis C co-infection, use of lopinavir- or abacavir-based ART, and a longer duration of lopinavir exposure. Conversely, reductions in CVD risk were linked to higher educational attainment, use of antihypertensive or lipid-lowering therapy, and adherence to a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-based antiretroviral therapy regimen.
Conclusions: CVD risk in PLHIV is dynamic and modifiable. The use of NNRTI-based regimens and lipid-lowering therapies contributed to a significant risk reduction. Comprehensive integrated management strategies addressing both HIV infection and cardiovascular health are essential. Further research is needed on the cardiovascular effects of integrase inhibitors (INSTIs), particularly their long-term effects on lipid profiles and endothelial function.</dc:description>
	<dc:publisher xml:lang="en-US">Universitas Airlangga</dc:publisher>
	<dc:date>2026-02-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://e-journal.unair.ac.id/JNERS/article/view/72933</dc:identifier>
	<dc:identifier>10.20473/jn.v21i1.72933</dc:identifier>
	<dc:source xml:lang="en-US">Jurnal Ners; Vol. 21 No. 1 (2026): VOLUME 21 ISSUE 1 (FEBRUARY 2026); 67-75</dc:source>
	<dc:source>2502-5791</dc:source>
	<dc:source>1858-3598</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://e-journal.unair.ac.id/JNERS/article/view/72933/36699</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2026 Jurnal Ners</dc:rights>
	<dc:rights xml:lang="en-US">http://creativecommons.org/licenses/by/4.0</dc:rights>
</oai_dc:dc>